These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9578636)

  • 21. Simulated dipeptide recognition by vancomycin.
    Li D; Sreenivasan U; Juranic N; Macura S; Puga FJ; Frohnert PM; Axelsen PH
    J Mol Recognit; 1997; 10(2):73-87. PubMed ID: 9376130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calculation of concentrations of equilibrium components in an in vitro activity test of vancomycin antibiotics and the possible mode of action.
    Yan H; Cheng X; He B
    Biophys Chem; 1998 Aug; 74(2):107-15. PubMed ID: 9760722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An analysis of the origins of a cooperative binding energy of dimerization.
    Williams DH; Maguire AJ; Tsuzuki W; Westwell MS
    Science; 1998 May; 280(5364):711-4. PubMed ID: 9563941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surface Ligand Density of Antibiotic-Nanoparticle Conjugates Enhances Target Avidity and Membrane Permeabilization of Vancomycin-Resistant Bacteria.
    Hassan MM; Ranzoni A; Phetsang W; Blaskovich MA; Cooper MA
    Bioconjug Chem; 2017 Feb; 28(2):353-361. PubMed ID: 27959504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigations into self-association of vancomycin covalent dimers using surface plasmon resonance technology.
    Adamczyk M; Moore JA; Rege SD; Yu Z
    Bioorg Med Chem Lett; 1999 Aug; 9(16):2437-40. PubMed ID: 10476883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A rational strategy for enhancing the affinity of vancomycin towards depsipeptide ligands.
    Axelsen PH; Li D
    Bioorg Med Chem; 1998 Jul; 6(7):877-81. PubMed ID: 9730223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure of balhimycin and its complex with solvent molecules.
    Schäfer M; Sheldrick GM; Schneider TR; Vértesy L
    Acta Crystallogr D Biol Crystallogr; 1998 Mar; 54(Pt 2):175-83. PubMed ID: 9761883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oritavancin Retains a High Affinity for a Vancomycin-Resistant Cell-Wall Precursor via Its Bivalent Motifs of Interaction.
    Bowden S; Joseph C; Tang S; Cannon J; Francis E; Zhou M; Baker JR; Choi SK
    Biochemistry; 2018 May; 57(18):2723-2732. PubMed ID: 29651842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala.
    Ge M; Chen Z; Onishi HR; Kohler J; Silver LL; Kerns R; Fukuzawa S; Thompson C; Kahne D
    Science; 1999 Apr; 284(5413):507-11. PubMed ID: 10205063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of transglycosylation involved in bacterial peptidoglycan synthesis.
    Goldman RC; Gange D
    Curr Med Chem; 2000 Aug; 7(8):801-20. PubMed ID: 10828288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of action of oritavancin and related glycopeptide antibiotics.
    Allen NE; Nicas TI
    FEMS Microbiol Rev; 2003 Jan; 26(5):511-32. PubMed ID: 12586393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis of rigidly-linked vancomycin dimers and their in vivo efficacy against resistant bacteria.
    Lu J; Yoshida O; Hayashi S; Arimoto H
    Chem Commun (Camb); 2007 Jan; (3):251-3. PubMed ID: 17299629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding interactions of vancomycin tracers with a bacterial cell wall peptidoglycan analogue.
    Adamczyk M; Grote J; Moore JA; Rege SD; Yu Z
    Bioorg Med Chem Lett; 2000 Jul; 10(14):1613-5. PubMed ID: 10915064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular interactions between glycopeptide vancomycin and bacterial cell wall peptide analogues.
    Xing B; Jiang T; Wu X; Liew R; Zhou J; Zhang D; Yeow EK
    Chemistry; 2011 Dec; 17(50):14170-7. PubMed ID: 22083883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vancomycin dimerization and chiral recognition studied by high-performance liquid chromatography.
    Slama I; Dufresne C; Jourdan E; Fahrat F; Villet A; Ravel A; Grosset C; Peyrin E
    Anal Chem; 2002 Oct; 74(20):5205-11. PubMed ID: 12403572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of high-affinity peptide ligands for vancomycin.
    Yao N; Wu CY; Xiao W; Lam KS
    Biopolymers; 2008; 90(3):421-32. PubMed ID: 18260149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. D-Ala-D-lac binding is not required for the high activity of vancomycin dimers against vancomycin resistant enterococci.
    Jain RK; Trias J; Ellman JA
    J Am Chem Soc; 2003 Jul; 125(29):8740-1. PubMed ID: 12862465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vancomycin dimer formation between analogues of bacterial peptidoglycan surfaces probed by force spectroscopy.
    Batchelor M; Zhou D; Cooper MA; Abell C; Rayment T
    Org Biomol Chem; 2010 Mar; 8(5):1142-8. PubMed ID: 20165806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modification and inhibition of vancomycin group antibiotics by formaldehyde and acetaldehyde.
    Heck AJ; Bonnici PJ; Breukink E; Morris D; Wills M
    Chemistry; 2001; 7(4):910-6. PubMed ID: 11288883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of configurational entropy in biochemical cooperativity.
    Jusuf S; Loll PJ; Axelsen PH
    J Am Chem Soc; 2002 Apr; 124(14):3490-1. PubMed ID: 11929222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.